Results 11 to 20 of about 17,288 (263)

Desmopressin for bleeding in non‐severe hemophilia A: Suboptimal use in a real‐world setting

Research and Practice in Thrombosis and Haemostasis, 2022
Background Desmopressin is an important treatment option in nonsevere hemophilia A because it has several benefits compared with factor (F) concentrates, including no inhibitor risk and much lower costs.
Anne‐Fleur Zwagemaker, Fabienne R. Kloosterman, Michiel Coppens, Samantha C. Gouw, Sara Boyce, Catherine N. Bagot, Erik A. M. Beckers, Paul Brons, Giancarlo Castaman, Jeroen Eikenboom, Shannon Jackson, Marieke J. H. A. Kruip, Frank W. G. Leebeek, Karina Meijer, Laurens Nieuwenhuizen, Ingrid Pabinger, Karin Fijnvandraat, the DYNAMO Study Group   +17 more
doaj   +2 more sources

Association between winter season and desmopressin treatment efficiency in children with monosymptomatic nocturnal enuresis: a pilot study

International Brazilian Journal of Urology, 2022
Objectives: The purpose of our study was to assess the association between the winter season and desmopressin treatment failure in South Chinese children with monosymptomatic nocturnal enuresis (MNE).
Mengkui Sun, Shoulin Li, Xuerui Sun, Zhimei Deng, Yanan Xu   +4 more
doaj   +2 more sources

Desmopressin in moderate hemophilia A patients: a treatment worth considering

Haematologica, 2018
Desmopressin increases endogenous factor VIII levels in hemophilia A. Large inter-individual variation in the response to desmopressin is observed.
Janneke I. Loomans, Marieke J.H.A. Kruip, Manuel Carcao, Shannon Jackson, Alice S. van Velzen, Marjolein Peters, Elena Santagostino, Helen Platokouki, Erik Beckers, Jan Voorberg, Johanna G. van der Bom, Karin Fijnvandraat, for the RISE consortium   +12 more
doaj   +2 more sources

Desmopressin and bleeding risk after percutaneous kidney biopsy

BMC Nephrology, 2019
Background Desmopressin is used to reduce bleeding after kidney biopsy but evidence supporting its use is weak, especially in patients with elevated creatinine.
Ambarish Athavale, Hemant Kulkarni, Cagil D. Arslan, Peter Hart   +3 more
doaj   +2 more sources

Desmopressin and the risk of hyponatremia: A population-based cohort study.

PLoS Medicine, 2019
BACKGROUND:Desmopressin was approved by the Food and Drug Administration (FDA) in 1978 for use in diabetes insipidus and bleeding disorders, but it is also prescribed off-label for patients with nocturia.
Michael Fralick, Sebastian Schneeweiss, Christopher J D Wallis, Emily H Jung, Aaron S Kesselheim   +4 more
doaj   +2 more sources

Use of Desmopressin in Hyponatremia: Foe and Friend

Kidney Medicine, 2019
Use of desmopressin (1-deamino-8-d-arginine vasopressin; DDAVP), a synthetic vasopressin receptor agonist, has expanded in recent years. Desmopressin leads to renal water retention, and iatrogenic hyponatremia may result if fluid intake is not ...
Steven G. Achinger, Juan Carlos Ayus
doaj   +2 more sources

Serum sodium and intracranial pressure changes after desmopressin therapy in severe traumatic brain injury patients: a multi-centre cohort study

Annals of Intensive Care, 2019
Background In traumatic brain injury (TBI) patients desmopressin administration may induce rapid decreases in serum sodium and increase intracranial pressure (ICP).
A. Harrois, J. R. Anstey, F. S. Taccone, A. A. Udy, G. Citerio, J. Duranteau, C. Ichai, R. Badenes, J. R. Prowle, A. Ercole, M. Oddo, A. Schneider, M. van der Jagt, S. Wolf, R. Helbok, D. W. Nelson, M. B. Skrifvars, D. J. Cooper, R. Bellomo, The TBI Collaborative   +19 more
doaj   +2 more sources

Desmopressin for treating nocturia in men [PDF]

BJU International, 2017
ObjectivesTo assess the effects of desmopressin as compared to other interventions in the treatment of nocturia in men.Materials and MethodsWe performed a comprehensive search using multiple databases and abstract proceedings with no restrictions on the language of publication or publication status, up until August 2017. We included randomised or quasi‐
Mark H. Ebell, Julia Han, Philipp Dahm, Philipp Dahm, Jae Hung Jung, Jae Hung Jung, Jae Hung Jung, Caitlin J Bakker   +7 more
openaire   +6 more sources

Desmopressin to reduce periprocedural bleeding and transfusion: a systematic review and meta-analysis

Perioperative Medicine
We systematically reviewed the literature to investigate the effects of peri-procedural desmopressin in patients without known inherited bleeding disorders undergoing surgery or other invasive procedures.
Carol Wang, Victoria Lebedeva, Jeffy Yang, Joshua Anih, Lily J. Park, Freeman Paczkowski, Pavel S. Roshanov   +6 more
doaj   +2 more sources

von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD

Blood Advances, 2019
: The bleeding phenotype of patients with type 1 von Willebrand disease (VWD) is very heterogeneous. We hypothesized that this heterogeneity may partly be explained by variability in response of von Willebrand factor (VWF) and factor VIII (FVIII) levels ...
Ferdows Atiq, Lisette M. Schütte, Agnes E.M. Looijen, Johan Boender, Marjon H. Cnossen, Jeroen Eikenboom, Moniek P.M. de Maat, Marieke J. H.A. Kruip, Frank W.G. Leebeek   +8 more
doaj   +2 more sources